Abound Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Abound Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09K	Hold	4	–	–	﹤0.01%	810
2026 Q1	$1.44K	Hold	4	–	–	﹤0.01%	951
2025 Q4	$1.73K	Hold	4	–	–	﹤0.01%	869
2025 Q3	$1.65K	Buy	4 +1	+33%	+$407	﹤0.01%	831
2025 Q2	$979	Hold	3	–	–	﹤0.01%	805
2025 Q1	$811	Sell	3 -1	-25%	-$257	﹤0.01%	774
2024 Q4	$885	Buy	4 +1	+33%	+$263	﹤0.01%	749
2024 Q3	$826	Buy	+3	New	+$781	﹤0.01%	799
2024 Q2	–	Sell	-3	Closed	-$449	–	1175
2024 Q1	$449	Sell	3 -1	-25%	-$167	﹤0.01%	928
2023 Q4	$706	Buy	4 +1	+33%	+$170	﹤0.01%	845
2023 Q3	$532	Hold	3	–	–	﹤0.01%	796
2023 Q2	$570	Buy	+3	New	+$595	﹤0.01%	807

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Abound Wealth Management's ALNY Position: Q2 2026 in Review

Abound Wealth Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 4 shares worth $1.09K. The position accounts for ﹤0.01% of the portfolio, ranked #810.

Abound Wealth Management first reported a position in ALNY in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.73K in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Abound Wealth Management held 4 shares of Alnylam Pharmaceuticals worth $1.09K as of Q2 2026.
Abound Wealth Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #810 holding.
Abound Wealth Management first reported a position in Alnylam Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
Abound Wealth Management's Alnylam Pharmaceuticals position peaked at $1.73K in Q4 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.